ArticleThe Journal of clinical investigation1996
Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts.
Article in The Journal of clinical investigation, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
202 citing papers in PubMed, 1,135 citations in OpenAlex.
- Embryoid bodies as a model system for exploring early human embryonic development.Journal of assisted reproduction and genetics · 2025Review
- Pluripotent stem cell-derived organoids: A brief history of curiosity-led discoveries.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Low-adhesion culture selection for human iPS cell-derived cardiomyocytes.Scientific reports · 2024Article
- PD-L1 and AKT Overexpressing Adipose-Derived Mesenchymal Stem Cells Enhance Myocardial Protection by Upregulating CD25International journal of molecular sciences · 2023Article
- Assessment of arrhythmia mechanism and burden of the infarcted ventricles following remuscularization with pluripotent stem cell-derived cardiomyocyte patches using patient-derived models.Cardiovascular research · 2022Article
- Application of hiPSC as a Drug TesterFrontiers in genetics · 2022Review
- Fluorescent PSC-Derived Cardiomyocyte Reporter Lines: Generation Approaches and Their Applications in Cardiovascular Medicine.Biology · 2020Review
- Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models.Animals : an open access journal from MDPI · 2020Review
- Regulation of cardiomyocyte maturation during critical perinatal window.The Journal of physiology · 2020Review
- JNK Signaling in Stem Cell Self-Renewal and Differentiation.International journal of molecular sciences · 2020Review
- Stem cell therapy of myocardial infarction: a promising opportunity in bioengineering.Advanced therapeutics · 2020Article
- Multiplex live single-cell transcriptional analysis demarcates cellular functional heterogeneity.eLife · 2019Article
- A comprehensive, multiscale framework for evaluation of arrhythmias arising from cell therapy in the whole post-myocardial infarcted heart.Scientific reports · 2019Article
- Cardiac tissue engineering: current state-of-the-art materials, cells and tissue formation.Einstein (Sao Paulo, Brazil) · 2018Review
- Can We Engineer a Human Cardiac Patch for Therapy?Circulation research · 2018Review
- The Heart and Great Vessels.Cold Spring Harbor perspectives in medicine · 2018Review
- Article
- Engineering Scalable Manufacturing of High-Quality Stem Cell-Derived Cardiomyocytes for Cardiac Tissue Repair.Frontiers in medicine · 2018Review
- Hypoxia favors myosin heavy chain beta gene expression in an Hif-1alpha-dependent manner.Oncotarget · 2017Article
- Remuscularization of the failing heart.The Journal of physiology · 2017Review
142 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
This study describes a simple approach to generate relatively pure cultures of cardiomyocytes from differentiating murine embryonic stem (ES) cells. A fusion gene consisting of the alpha-cardiac myosin heavy chain promoter and a cDNA encoding aminoglycoside phosphotransferase was stably transfected into pluripotent ES cells. The resulting cell lines were differentiated in vitro and subjected to G418 selection. Immunocytological and ultrastructural analyses demonstrated that the selected cardiomyocyte cultures (> 99% pure) were highly differentiated. G418 selected cardiomyocytes were tested for their ability to form grafts in the hearts of adult dystrophic mice. The fate of the engrafted cells was monitored by antidystrophin immunohistology, as well as by PCR analysis with primers specific for the myosin heavy chain-aminoglycoside phosphotransferase transgene. Both analyses revealed the presence of ES-derived cardiomyocyte grafts for as long as 7 wk after implantation, the latest time point analyzed. These studies indicate that a simple genetic manipulation can be used to select essentially pure cultures of cardiomyocytes from differentiating ES cells. Moreover, the resulting cardiomyocytes are suitable for the formation of intracardiac grafts. This selection approach should be applicable to all ES-derived cell lineages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.